Elexacaftor/tezacaftor/ivacaftor

Elexacaftor/tezacaftor/ivacaftor
Combination of
Elexacaftor	Cystic fibrosis transmembrane conductance regulator (CFTR) corrector
Tezacaftor	CFTR corrector
Ivacaftor	Chloride channel opener
Clinical data
Trade names	Trikafta, Kaftrio
AHFS/Drugs.com	Monograph
MedlinePlus	a619061
License data	US DailyMed: Elexacaftor, tezacaftor, and ivacaftor;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	R07AX32 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	2398469-65-1;
KEGG	D11700;

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.

It is approved for use in the United States for people aged two years and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene. It is also approved for use in Canada, the European Union, and Australia.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.